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Abstract Muscle remodeling is an important physiological
process that promotes adaptive changes in cytoarchitecture
and protein composition after exercise, aging, or disease
conditions. Numerous transcription factors have been
reported to regulate skeletal muscle homeostasis. NF-κB
is a major pleiotropic transcription factor modulating
immune, inflammatory, cell survival, and proliferating
responses; however, its role in muscle development,
physiology, and disease has just started to be elucidated.
The current review article aims to summarize the literature
on the role of NF-κB signaling in skeletal muscle
pathophysiology, investigated over the last years using in
vitro and more recently in vivo systems. Understanding the
exact role of NF-κB in muscle cells will allow better
therapeutic manipulations in the setting of human muscle
diseases.
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NF-κB signaling pathway
Nuclear factor κb (NF-κB) transcription factors are evolu-
tionary conserved signaling molecules that play a critical
role in many biological processes, including innate and
adaptive immunity [1], tumorogenesis [2], as well as tissue
development and disease [3–9]. Mammalian cells have five
NF-κB family members, RelA (p65), cRel, RelB, p50/p105
(NF-κB1), and p52/p100 (NF-κB2) [10]. Each member of
the NF-κB transcription factor family, besides RelB, can
form homodimers as well as heterodimers with one another
[1]. All NF-κB subunits are characterized by a highly
conserved 300 amino acid N-terminal domain, called Rel
homology domain (RHD), that mediates (a) binding to
promoters and enhancer regions containing κB sites (5′
GGGRNNYYCC3′, N=any base, R=purine, and Y=pyrim-
idine) [11], (b) subunit dimerization, and (c) interaction
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with inhibitory proteins, known as IκBs [12]. NF-κB
complexes act either as inducers or repressors of gene
expression [11]. The main transcriptional activated forms of
NF-κB are the heterodimers p65/p50 or p65/p52 [11], while
homodimers such as p50/50 or p52/p52 are transcription-
ally repressive [1, 13].
NF-κB-mediated signaling has been most extensively
studied in the immune system. In the vast majority of
unstimulated cells, NF-κB dimers are retained in the
cytoplasm through association with IκBs. There are five
classical inhibitors of NF-κB (IκBs)—IκBα, IκBβ, IκBγ,
IκBɛ, and Bcl-3, which contain ankyrin (ANK) repeats and
a 33 amino acid motif responsible for mediating protein–
protein interaction [1, 11]. Since p100 and p105 also
contain ANK repeats, they can function as IκB-like
proteins, besides their role as NF-κB nuclear transcription
factors [14, 15]. Although the biological relevance of the
different IκB proteins has still to be explored in depth [1],
their most common function is binding to NF-κB dimers to
regulate the shuttling between the cytoplasm and nucleus
[16]. The balance between cytoplasmic and nuclear
localization is altered upon IκBα degradation since it
removes the contribution of the IκB nuclear export
sequence (NES) and exposes the masked NLS of the NF-
κB subunits, resulting in predominantly nuclear localization
of NF-κB [17]. Finally, Bcl-3 is an unusual member of the
IκBs, which interacts specifically with p50 and p52
homodimers and, in contrast to the other IκBs, induces
the expression of NF-κB-regulated genes [18]. The differ-
ent components of the pathway, as discussed in the
following paragraphs, are schematically illustrated in Fig. 1.
The rapid activation and nuclear translocation of
cytoplasmic NF-κB, in the “classical” or “canonical”
pathway, is the result of phosphorylation of the inhibitory
IκB by the activated IκB kinase (IKK) complex [19]. The
IKK complex consists of two catalytic subunits, named
IKKα/IKK1 and IKKβ/IKK2 [20] and one regulatory
subunit, named NF-κB essential modulator (IKKγ/NEMO)
[21]. Upon encountering a variety of stimuli, including
tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and
other growth factors, IκBα is phosphorylated and degraded
through the ubiquitination pathway, rendering NF-κB free
to translocate to the nucleus and bind to its target genes [10]
(Fig. 1).
The ubiquitin–proteasome pathway controls the mode of
activation of NF-κB, since phosphorylation is required for
the ubiquitination of IκBα. Interestingly, the ubiquitin
pathway is also implicated in the proteolysis of p100 and
p105 [22]. Moreover, recent studies have also identified
several ubiquitin pathway components that function up-
stream of IKK subunits, including the TRAF proteins as E3
ubiquitinase ligases and TAB2 and TAB3 as ubiquitin
receptors (discussed in [22]). The mechanism that under-
lines the formation of polyubiquitin chains as well as the
different ubiquitin-conjugated enzymes (E2s) or ubiquitin-
protein ligases (E3s) involved in the ubiquitin–proteasome
and control NF-κB pathway remains to be fully elucidated.
Some NF-κB activators, such as B cell-activating factor of
the TNF family (BAFF), lipopolysaccharide (LPS), stimula-
tion of CD40 and lymphotoxin-β receptors and latent
membrane protein-1 of Epstein–Barr virus, can activate the
“non-canonical” or “alternative” pathway [23]. In this case,
activation of NF-κB-inducing kinase (NIK) results in
homodimerization of IKKα, which then phosphorylates the
p100 NF-κB subunit, inducing its proteolytic processing to
p52. As a consequence, activated p52/RelB heterodimers
enter the nucleus and target distinct κB elements [19] (Fig. 1).
Besides the NF-κB-dependent effects of IKKs, more
functions for IKKs that are independent from the NF-κB
pathway have been described. For example, IKKα can
phosphorylate histone H3 [24], through interaction with the
transcriptional co-activator cyclic AMP-responsive element
binding (CREB)-binding protein (CBP) [25]. IKKα also
seems to regulate cyclin D1 expression through other
mechanisms, including phosphorylation and activation of
the estrogen receptor-α (ERα) transcription factor [26],
phosphorylation and stabilization of β-catenin [27], or even
direct phosphorylation of cyclin D1 protein [28]. Moreover,
IKKα could have other effects, independent of NF-κB
activation, in keratinocyte differentiation [8, 29] and tooth
development [30]. Such independent functions have also
been proposed for the IKKβ subunit. Specifically, IKKβ
has been shown to phosphorylate and inhibit FOXO3a,
resulting in the enhancement of IKK-dependent induction
of tumorogenesis in mammary glands [31]. IKKβ can also
phosphorylate 14-3-3β and inhibit TPP-14-3-3β ARE
binding and might therefore regulate mRNA stability [32].
In the same context, IKKγ (NEMO) subunit has also the
ability to translocate to the nucleus following DNA damage
and stimulate the interaction of CBP with hypoxia-
inducible factor-2α (HIF-2α), enhancing the transcriptional
activity of HIF-2α [33]. These independent effects of the
IKK subunits (Fig. 1) have recently evolved, and further
investigation is needed to define the exact mechanisms that
allow action through NF-κB-independent activation.
But which are the upstream signaling pathways that lead
to IKK or NF-κB activation? Different signals, such as
TNF, interleukins, and various stress signals, all activate the
IKK complex. More specifically, activation of the TNF
receptor results in its trimerization and recruitment of the
adaptor protein TRADD (TNF receptor associated via death
domain), which, in turn, interacts with TRAF2 (TNF-
receptor-associated factor 2). Consequently, receptor-inter-
acting protein (RIP) and MAP/ERK kinase kinase 3
(MEKK3) link TNF signaling to IKK activation [16]
(Fig. 1). In addition, specific receptors, which lead to IKK
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activation, recognize many pathogen substrates such as
LPS, lipoproteins, or other compounds [1]. The most
common pathogen receptors are the Toll-like receptors
(TLR) and so far ten members of the TLR family have been
reported [34]. LPS binding to TLRs activates an intracel-
lular signaling cascade that involves recruitment of MYD88
(myeloid differentiation primary response gene 88) and
IRAK (interleukin-1-receptor-associated kinase), phosphor-
ylation of TRAF6 (TNF-receptor-associated factor 6),
which then signals through the TAB2–TAK1–TAB1 com-
plex to activate the IKK complex [34] (Fig. 1). Moreover,
in peripheral T cells, T cell receptors (TCRs) are responsi-
ble for activation of the NF-κB pathway [16]. T cell
stimulation results in PKCθ activation (protein kinase Cθ),
which signals via the CARMA1–BCL-10–MALT1 com-
plex to activate the IKK complex [16] (Fig. 1).
Fig. 1 An outline of major signaling pathways leading to NF-κB
activation. The best characterized NF-κB activators include TCR
signaling, TNF, TLR, LTβR, and INF-γR signaling. Activation of
TNF receptor results in its trimerization and recruitment of the adaptor
protein TRADD, which, in turn, interacts with TRAF2. Consequently,
RIP and MEKK3 link TNF signaling to IKK activation. LPS binding
to TLRs activates an intracellular signaling cascade that involves
recruitment of MYD88 and IRAK, phosphorylation of TRAF6, which
then signals through the TAB2–TAK1–TAB1 complex to activate the
IKK complex. In peripheral T cells, T cell stimulation results in PKCθ
activation, which signals via the CARMA1–BCL-10–MALT1 com-
plex to activate the IKK complex. INF-γR1 can recruit MyD88, and
through MLK3 activates p38. Convergence point for most of the
above cascades is the activated IκB kinase (IKK) complex, which
consists of three subunits: IKK1, IKK2, and NEMO. Upon IKK
activation, IκBα is phosphorylated and degraded through the
ubiquitination pathway, rendering NF-κB free to translocate to the
nucleus and bind to its target genes (canonical pathway). In other
cases, IKK stimulation leads to p105/p50 activation and subsequent
binding of Bcl3 to the p50/p50 homodimers. The p50/p50-Bcl3
complex translocates to the nucleus and induces NF-κB dependent
transcription. Some activators such as BAFF or LPS can activate the
non-canonical pathway. Here, activation of NF-κB-inducing kinase
(NIK) results in homodimerization of IKK1, which then phosphor-
ylates the p100 NF-κB subunit, inducing its proteolytic processing to
p52. Besides their NF-κB-dependent effects, more functions indepen-
dent of the NF-κB pathway have been described for IKKs. IKK1 can
phosphorylate histone H3, through interaction with the transcriptional
co-activator CBP. NEMO has also the ability to translocate to the
nucleus following DNA damage. Nuclear NEMO is sumoylated and
then ubiquitinated, in a process that depends on ATM kinase. Then,
NEMO together with ATM translocate to the cytoplasm where it
activates IKK2. TCR T cell receptor, TNFR tumor necrosis factor
receptor, TLR Toll-like receptor, INF-γR1: interferon-γ receptor 1,
RANK receptor activator of NF-κB, PKCθ protein kinase Cθ,
CARMA1 caspase-associated recruitment domain-1, BCL-10 B cell
lymphoma 10, MALT1 mucosa-associated lymphoid tissue lymphoma
translocation gene 1, MEKK3 MAP/ERK kinase kinase 3, RIP
receptor-interacting protein, TRADD TNF receptor associated via
death domain, TRAF TNF-receptor-associated factor, IRAK interleu-
kin-1-receptor-associated kinase, MYD88 myeloid differentiation
primary response gene 88, TAK1 transforming-growth-factor-β-acti-
vated kinase 1, TAB1 TAK1-binding protein 1, TAB2 TAK1-binding
protein 2, ATM ataxia-telangiestasia-mutated kinase, IκB inhibitor of
κB, IKK IκB kinase, NEMO NF-κB essential modulator, Ub ubiquitin,
NIK NF-κB-inducing kinase, MLK3 mixed-lineage kinase 3, CBP
CREB-binding protein, BCL-3 B cell lymphoma 3, TCR T cell
receptor, TNF tumor necrosis factor, LTβR lymphotoxin-β receptor,
INF-γR interferon-γ receptor
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From this overview, it is clear that cells of the immune
system have been particularly advantageous for elucidating
a large number of NF-κB regulatory mechanisms. The
presence of different activators, the variety of IκB proteins,
NF-κB dimers, and post-transcriptional modifications of the
NF-κB subunits, together with the crosstalk with other
transcription factors and the independent effects of the
IKKs, reflect the high diversity of this pathway, which is
not limited to the immune system alone.
Role of NF-κB in muscle formation
The IKK/NF-κB signaling cascade and the mechanisms
that regulate it have not been explored in as much depth in
other cell types. The importance of NF-κB signaling in
tissues, such as liver [35, 36], brain [7, 37, 38], and skin [6,
8, 39–41], has only recently received attention. Concomi-
tantly, the potential contribution of the NF-κB pathway
during muscle development has also started to emerge over
the last years and this review will discuss the literature on
the contribution of NF-κB in skeletal muscle formation.
Muscle is the contractile tissue of the body, which
functions via force production to cause movements of all
body parts. Studies using muscle cell lines revealed that
p65 is abundant in rat L6 muscle cell nuclei [42], while
murine C2C12 skeletal muscle cell lines contain p65/p50 in
their nuclei [43]. Although the p65/p50 heterodimer is the
most commonly studied form of NF-κB, recently, other
combinations have been revealed in skeletal muscles from
viable total knockout mice of various NF-κB subunits. c-
Rel protein is expressed in low levels in skeletal muscle
[44], while c-Rel−/− [44] and also p50−/− and Bcl-3−/−
muscles [45] do not show differences in NF-κB activity or
fiber morphology under state-stage conditions, indicating
that these NF-κB subunits are not highly important during
muscle development. However, upon disease conditions,
such as unloading-induced atrophy, complexes comprising
p50 and Bcl-3 subunits [45], but not c-Rel [44], are
activated and translocate into the nucleus in order to
regulate transcription of target genes.
Concerning the target genes of NF-κB activation in
skeletal muscle, it was described that in the C2C12
myoblast cell line, NF-κB binds on κB sites of the cyclin
D1 promoter, regulates its transcription [43], and leads to
progression into the S phase of cell cycle. The binding
activity of NF-κB on cyclin D1 is reduced during myo-
genesis, suggesting that NF-κB plays an important role for
transition from the proliferation to the differentiation stage
[43]. The notion that NF-κB acts as a negative regulator of
late-stage muscle differentiation was supported by recent
demonstration that the p65/p50 heterodimer complex binds
to the transcriptional repressor YinYang1 (YY1) and results
in inhibition of skeletal myogenesis, via transcriptional
silencing of myofibrillar genes [46]. Interestingly, transcrip-
tional regulation of NF-κB depends on the muscle’s state. It
was shown that upon atrophy conditions, NF-κB binds on
the promoter of murine ring finger-1 (MuRF1) [4], an E3
ubiquitin ligase known to be involved in multiple models of
skeletal muscle atrophy [47], and increases its expression,
supporting the notion that NF-κB can also regulate the
ubiquitin pathway. Although MuRF1 is not the only critical
mediator of muscle atrophy [4], additional NF-κB muscle
targets in this pathway have not yet been described.
In addition to the identification of transcriptional NF-κB
targets, potential upstream activators of NF-κB in skeletal
muscle function have been extensively studied. Different
research laboratories [48–58] have analyzed the effect of
TNF-α in muscles. TNF-α is also called cachectin because
it was found in the urine of cancer patients who suffer from
muscle cachexia [59], a syndrome characterized by extreme
weight loss and body wasting. Although TNF knockout
mice do not show any distinct muscle phenotype under
state-stage conditions [48], when human recombinant TNF
was added to proliferating myoblasts, cell fusion as well as
muscle differentiation was inhibited [58]. Interestingly,
TNF-α inhibition of myogenesis was mediated through
repressed synthesis of MyoD at the post-transcriptional
level [60]. Similarly, recent studies showed that treatment of
C2C12 myoblasts with TNF-like weak inducer of apoptosis
(TWEAK) resulted in NF-κB activation and degradation of
MyoD protein [49]. Consistently, two downstream regu-
lators of the TNF-α pathway, namely receptor-interacting
protein 2 (RIP2) and TNF-associated factor 2 (TRAF2),
also negatively regulate myogenesis [61–63] (Fig. 2).
A new mechanism has recently emerged whereby TNF-
α inhibits muscle differentiation through activation of
caspases in the absence of apoptosis [54]. Expression of
both PW1 and Bax is required to mediate this response.
PW1 (also named as paternally expressed gene 3 or Peg3
[64]) is expressed at high levels both in developing skeletal
muscle and in muscle cell lines. PW1 interacts with TRAF2
and participates in the TNF-α signal transduction pathway
[65, 66]. Although the exact function of PW1 in muscle
cells is not yet completely understood, this study implies
that the interaction of TRAF2 with PW1 induces translo-
cation of some components of cell death effectors (such as
Bax proteins) in mitochondria and activation of caspases
[54] (Fig. 2).
Besides its role in myogenic differentiation, TNF-α is
also important for the activation of satellite cells during
muscle regeneration [50]. Interestingly, a key activator
during this process is believed to be the MAP kinase p38
[50] (Fig. 2), a protein that controls skeletal muscle
differentiation [67], although the exact downstream targets
of TNF-α, which lead to p38 activation, remain to be
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established. It is likely that upon injury, TNF-α activates
satellite cells to enter the cell cycle and accelerates G1-to-S
phase transition, involving activation of early response
genes [57].
Moreover, TNF-α appears to stimulate general proteol-
ysis by increasing ubiquitin conjugation to muscle proteins
[68]. In this process, the ubiquitin-activating enzyme (E1
protein) activates ubiquitin, which is then transferred to an
ubiquitin carrier protein (E2). The ubiquitin carrier protein
interacts with an ubiquitin ligase (E3) to catalyze transfer of
ubiquitin to the protein substrate, marking the substrate for
proteasome degradation as ubiquitin accumulates [69].
According to the proposed mechanism, the TNF-α/NF-κB
pathway promotes the loss of muscle protein through
increased transcription of an E2 ubiquitin carrier protein
that called UbcH2/E220k gene [68]. Although it was
suggested that UbcH2 interacts with one or more ubiquitin
ligases [68], it still remains unclear whether this interaction
can occur with known NF-κB candidates of muscle atrophy
such as MuRF1 [4].
Aside from the TNF-α signaling pathway, few studies
have also looked into the role of other cytokines during
muscle formation. For example, IL-6 has been proposed as
one of the effectors of the promyogenic mechanism of a
crosstalk between p38 MARK and NF-κB signaling in
C2C12 cells [70]. However, combination of TNF with other
inflammatory cytokines such as IL1-β or IL-6 had no effect
on skeletal muscle gene expression [60]. Similarly, human
IL-1α and 1β combined with TNF-α had no effect on the
regulation of protein balance in skeletal muscle [71].
Although interferon-γ (INF-γ) also had no effect on
C2C12 myotubes, when differentiated myotubes were
treated with a combination of TNF and INF-γ, a significant
reduction was seen in both MyoD and myosin heavy chain
(MyHC, a muscle differentiation marker) protein expres-
sion [60]. Thus, the synergistic effects of cytokines may
Fig. 2 NF-κB pathway in skeletal muscles. NF-κB binds on κB sites
of the cyclin D1 promoter and regulates its transcription. Moreover,
the p65/p50 heterodimer complex binds to the transcriptional repressor
YY1, resulting in inhibition of skeletal myogenesis. TNF-α and
TWEAK activation regulates MyoD1 expression through a p65/p50
complex. In response to TNF signaling, PW1 associates with TRAF2,
induces Bax translocation in mitochondria, and through activation of
caspases, leads to inhibition of muscle differentiation. TNF-α
signaling is important for the activation of satellite cells during
muscle regeneration, through the MAP kinase p38. Synergistic effects
of TNF and INF-γ result in muscle atrophy. Stable expression of
constitutively active CnA in C2C12 cells induces NF-κB activation in
a TNF-α-independent mechanism. Intracellular calcium in muscle
cells activates calpain 3, which induces IκBα degradation, leading to
NF-κB activation and translocation into the nucleus, where it regulates
expression of survival genes. Upon denervation-induced atrophy, NF-
κB binds on the promoter of MuRF1. Upon unloaded-induced
atrophy, complexes comprising of p50 and Bcl-3 subunits are
activated and translocate into the nucleus to regulate transcription of
target genes. MuRF1 Murine ring finger-1, YY1 YinYang1, PW1/Peg3
paternally expressed 3, TWEAK TNF weak inducer of apoptosis, CnA
activated form of calcineurin A, Bax Bcl-2-associated X protein,
TRAF2 TNF-receptor-associated factor 2, RIP receptor-interacting
protein, TNFR1 tumor necrosis factor receptor 1, INF-γR1 interferon-
γ receptor 1, IKK IκB kinase, NEMO NF-κB essential modulator
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have a higher impact on muscle function, implying that
activation of NF-κB via a single cytokine may be
insufficient to mediate profound differences in myogenic
expression.
In an attempt to link NF-κB with other important
signaling molecules, cell culture experiments in C2C12
cells showed that stable expression of constitutively active
calcineurin A (CnA) induced NF-κB activation (Fig. 2).
Surprisingly, CnA-induced NF-κB activation interfered
with terminal muscle differentiation, without the involve-
ment of TNF-α [72] suggesting that in skeletal muscles
non-cytokine-related cascades can also activate NF-κB.
Calpain 3-dependent activation of NF-κB constitutes
another example of TNF-α-independent regulation [3],
presumably by accumulation of IκBα in the sarcoplasm
due to calpain 3-dependent degradation. Excessive IκBα
traps NF-κB in the cytoplasm, blocks NF-κB translocation
to the nucleus, halts transcriptional expression of survival
genes and therefore sensitizes the muscle cells to apoptosis
[3] (Fig. 2).
In summary, myogenic cell lines respond to pro-
inflammatory cytokines by engaging the NF-κB pathway,
which acts as a mitogen in muscle proliferation and as a
negative regulator in late differentiation. So far, only few
components of the pathway that regulate muscle function
are known (highlighted in Fig. 2) where most of them are
extrapolated from cell culture experiments. Moreover, the
exact role of the NF-κB signaling pathway during skeletal
muscle development depends on the state of the cell, such
that skeletal muscles under physiological conditions have
lower NF-κB activity with different transcriptional profiles
compared to stressed muscles. The various transcriptional
mechanisms of NF-κB in skeletal muscle, in combination
with the synergistic effects of other signals such as p38,
calcineurin, or calpain 3 emphasize the necessity for further
studies to better understand the mechanisms behind the
diverse roles of NF-κB and to distinguish its function in
physiological and muscle disease conditions.
Muscle diseases and NF-κB
The potential role of NF-κB in skeletal muscle pathology
has received particular attention, since any severe function-
al dysregulation of skeletal muscle leads to weakness and
progressive tissue death. The most common pathology
associated with muscle disease is muscle atrophy which
causes a decrease in muscle mass. The etiological basis of
skeletal muscle atrophy includes cancer, AIDS, and heart
failure [73], but regardless of the cause, it is characterized
by a decrease in total protein, fiber diameter, and force
production [74]. Different techniques have been developed
in animal models to mimic the effects of muscle atrophy
and to dissect the molecular mechanisms that underlie this
pathological condition. Using immobilization studies in rats
[75] and mice [45], direct muscle injections of either
cytokines (TNF, INF-γ) or cancer cells [60], as well as
denervation of the sciatic nerve to induce muscle wasting
[4, 5] (Table 1), researchers have shown that NF-κB levels
are strongly upregulated upon muscle atrophy. Indeed,
attempts to inhibit the NF-κB pathway in several atrophy
models prevented muscle degeneration and myofiber death
[4, 5, 45, 75].
Sarcopenia is another form of muscle decline, a normal
consequence of aging that leads to a gradual inability to
maintain skeletal muscle function and mass [74]. In one
study, NF-κB protein concentrations were found to be
fourfold higher in elderly human muscles compared to
those of young people [76]. However, to date there are no
documented studies that investigate the exact mechanism
by which NF-κB acts in aging muscle.
Muscular dystrophies are inherited muscle diseases, of
which Duchenne muscular dystrophy (DMD) is the most
common. DMD is a X-linked recessive progressive muscle-
wasting disorder that results from the absence of the
dystrophin sarcomeric protein [77]. The most widely used
animal model for DMD is the mdx mouse, arising from a
spontaneous mutation in the dystrophin gene. Homozygous
animals are viable but present histological lesions similar to






Duchenne muscular dystrophy [81]




Inclusion body myositis [86]
Animal models
Muscular atrophy
Denervation (atrophy due to
nervous dysfunction)
Mice [4, 5]
Unloading (disuse atrophy) Rats,
mice
[45, 75]
Cancer cachexia Mice [4, 60]
TNF/INF-γ muscular injections Mice [60]
Muscular dystrophies
Mdx model Mice [83]
Double mdx/utr model Mice [83]
Toxin injection (regeneration model) Mice [5, 83, 102]
Freeze injury (regeneration model) Mice [103]
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the ones observed in human muscular dystrophy [78].
Dystrophy is characterized by muscle membrane damage,
chronic inflammation, necrosis, and severe muscle degen-
eration [77]. With time, repetitive rounds of damage and
repair in dystrophic muscles eventually exhaust the regen-
erative capacity of the tissue and lead to persistent
inflammation [79]. In particular, NF-κB-related cytokines,
such as TNF-α, were upregulated in dystrophic muscles
from DMD patients [80]. Moreover, cytoplasmic localiza-
tion of the p65 subunit of the NF-κB heterodimer is a
hallmark of regenerating muscle fibers in DMD patients
[81]. Consistently, dystrophic muscle cells have increased
susceptibility to oxidative stress as was shown in muscles
from both DMD patients and mdx mice. These observations
suggest that products of oxidative stress might be involved
in the dystrophic process, triggering an inflammatory
response [82] and leading to NF-κB activation. Interesting-
ly, recent studies [83] found that IKK/NF-κB signaling is
persistently elevated in immune cells and regenerating
muscle fibers in mdx mice as well as patients, supporting a
strong association of NF-κB activation with the dystrophic
phenotype. Indeed, another type of muscular dystrophy, the
limb-girdle muscular dystrophy type 2A (LGMD2A) has
also been affiliated with the NF-κB pathway. LGMD is
characterized by progressive symmetrical atrophy and
weakness at the proximal limb, scapular pelvic girdle, and
trunk muscles, without affecting facial muscles [84].
LGMD2A correlates with calpain 3 deficiency that leads
to myonuclear apoptosis through a mechanism mentioned
previously in this review (Fig. 2). According to this model,
calpain 3 controls IκBα turnover and indirectly regulates
NF-κB-dependent expression of survival genes, suggesting
an unexpected anti-apoptotic role of NF-κB in LGMD2A.
Inflammatory myopathies are another heterogeneous
group of muscle disorders that are defined by muscle
weakness and high infiltration of inflammatory cells in
muscle tissues [77]. Autoimmune inflammatory myopathies
can be classified into polymyosisitis (PM), dermatomyosi-
tis, and sporadic inclusion-body myositis (s-IBM), accord-
ing to differences in clinical and histopathological features
[85]. Strong expression of pro-inflammatory cytokines has
been reported in all inflammatory myopathies with higher
levels for TNF-α and IL-1 [85]. In PM patients, NF-κB
immunoreactivity has been observed in all regenerating
fibers and in 30–40% of fibers with features of necrosis and
phagocytosis [81]. Furthermore, muscle biopsies of eight
IBM patients were immunostained with specific antibodies
against p50 and p65 displayed approximately 70% of IBM
vacuolated muscle fibers with strong local accumulation of
both p50 and p65 subunits [86]. The differential distribu-
tions of NF-κB subunits in necrotic fibers, neuromuscular
junctions, and regenerating areas suggest different roles of
each subunit in muscle pathology.
A summary of the different human or animal model
diseases and their connection with the NF-κB signaling
pathway is shown in Table 1. NF-κB does not only play a
role in regulating myogenesis as suggested by myogenic
cultures, but it is likely to modulate immune responses,
muscle damage, and repair in DMD as well as in other
muscle disorders. The survival effect of NF-κB in
LGMD2A muscles compared with its rather negative
contribution in the other dystrophinopathies indicates
that this complicated area of biology has only begun to
unfold.
Genetic models of NF-κB signaling in skeletal muscles
Over the last years, different laboratories worked on
genetically manipulated transgenic and knockout mice that
were designed to interfere with one or more components of
the NF-κB pathway to mimic the diverse aspects of NF-κB
signaling in muscle pathophysiology. Substantial effort [48,
50, 55] has focused on the role of the TNF-α signaling
pathway during muscle regeneration. However, the results
are contradictory as the effects vary among the different
animal models (Table 2). More specifically, abnormal
regeneration, excess inflammation, and calcification were
observed in the regenerating soleus muscle of TNF-α
receptor double knockouts p55−/−/p75−/− [50], due to
impaired p38 activation [48]. On the other hand, regener-
ation studies on TNFα−/− and TNF-α and lymphotoxin-
alpha (LT-α, a TNF-α homologue, also called TNF-beta),
double knockout mice (TNFα−/−/LTα−/−), revealed no
major differences in the regeneration capacity [55]. Finally,
histopathological measurements on TNFα−/−/mdx animals
showed opposite results in diaphragm and quadriceps
muscles [87]. Although various injury models were used
in the above studies, their variable regeneration effects
suggest that TNF signaling might be under additional
regulation than just NF-κB activation in muscle reconstitu-
tion and therefore, it will be important to analyze mouse
models which affect downstream targets of TNF.
Two transgenic mouse models have been generated in
which NF-κB is either activated or inhibited selectively in
skeletal muscle by targeting the IKK2/IKKβ subunit of the
IKK complex. In MIKK mice, the muscle creatine kinase
(MCK) promoter was used to drive the expression of
constitutively active IKKβ (SS177/181EE mutant), while in
MISR mice the same promoter drove expression of the
dominant inhibitory IκBα (SS32/36AA mutant) [4]. MIKK
mice exhibited a severe muscle-wasting phenotype in both
limb and trunk muscles and a relative reduction in muscle
mass increasing with age. MISR mice showed decreased
muscle wasting both after denervation-induced atrophy and
after cancer cachexia [4]. These mouse models provided the
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first evidence that muscle-specific activation of IKKβ/NF-κB
pathway is sufficient to induce atrophy [4].
Further information about the role of NF-κB in muscle
pathophysiology came through analysis of knockout mice
that lacked single components of the signaling cascade. The
first NF-κB muscle specific knockout mouse was generated
by muscle-specific creatine kinase-driven Cre deletion
(MCK-Cre) of the IKK2 subunit [5]. In these mice, also
called IKK2mko (Table 2), the fiber number was altered and
muscle strength as well as physical performance was
improved, arguing that manipulations of the IKK activity
affect skeletal muscle physiology. Moreover, denervation-
induced atrophy in IKK2mko mice was minimal and in
addition the shift from a mixed to a faster fiber phenotype,
which is typically observed during muscle atrophy, was
abolished [5]. Consequently, muscle force in IKK2mko-
denervated muscles remained high, most likely due to a
synergistic effect of maintaining both muscle mass and
fiber integrity. Indeed, IKK2 muscle depletion stabilized
muscle homeostasis both by promoting protein synthesis
and attenuating protein degradation via the ubiquitinase-
ligase molecule muscle RING finger 1 (MuRF1) [5]. A
working model of NF-κB inhibition was proposed, in
which IKK2 depletion restabilizes a new ratio of protein/
degradation in response to the changes caused by muscle
atrophy [5] without affecting insulin and glucose homeo-
stasis [88]. Furthermore, it was demonstrated that the
combination of IGF1 supplementation with NF-κB inhibi-
tion further reduces the pathological symptoms of muscle
atrophy [5], implying that the NF-κB pathway can interfere
with other signals during muscle homeostasis.
Using cardiotoxin (CDX) injection as a model for
muscle injury [5], it was demonstrated that NF-κB
inhibition reduced inflammation and enhanced myoblast
contribution after local muscle damage, providing evidence
that the muscle regeneration process in IKK2mko animals
was accelerated. It is very likely that fusion and hypertrophic
growth have been enhanced through disruption of NF-κB
signaling [5]. Consistently, it was recently shown [83] that
deletion of IKK2 subunit under the control of the muscle
light chain promoter (MLC), in response to acute injury can
also lead to increased regeneration. In the context of DMD,
in mdx/MLC Cre/IKK2fl/fl muscles the increased number of
MyoD positive and neonatal MyHC cells [83] was
indicative for the formation of new fibers during muscle
reconstitution. Muscle regeneration, which occurs in re-
sponse to injury, involves inflammation and cytokine
stimulation that is produced by the infiltrating cells [79].
IKK2mko mice seem to accelerate regeneration in part by
limiting the inflammation process [5]. Indeed, myeloid-
specific lysozyme-driven Cre deletion (Lys-Cre) of the
IKK2 subunit in mdx mice (mdx/Lys Cre/IKK2fl/fl) revealed
that muscle pathology was noticeably improved [83].
Further studies have focused the role on specific NF-κB
subunits. Since p65−/− mice are not viable [10], the
regeneration properties of p65+/− heterozygous mice were
analyzed. Heterozygous deletion of p65, but not p50,
promotes regenerative myogenesis in mdx mice [83],
suggesting that the dystrophic pathology is selectively
regulated by the p65 subunit of the NF-κB dimer. These
mouse models were extremely useful, as they provided a
direct link between NF-κB-controlled activation and mus-
Table 2 Genetic models to study NF-κB function in skeletal muscle development and disease
Mouse models Reported muscle effect References
p55−/−/p75−/− Abnormal soleus regeneration (excess of inflammation, calcification) [48, 50]
TNFα−/− mice No difference in muscle regeneration [55]
TNFα−/−/LTα−/− mice No difference in muscle regeneration [55]
TNFα−/−/mdx Different effects on diaphragm and quadriceps [87]
TRAF2−/− mice Born with decreased muscle mass [63]
MISR mice (MCK-DNIκBα SS32/36AA) Reduced muscle loss under atrophy conditions [4]
MIKK mice (MCK-IKKβ SS177/181EE) Muscle atrophy [4]
IKK2mko (MCK Cre/IKK2fl/fl) Shifted muscle fiber distribution, improved muscle force,
protection against muscle atrophy, improved regeneration
[5]
mIGF1/IKK2mko Enhanced muscle atrophy protection [5]
MLC Cre/IKK2fl/fl Promotes regeneration [83]
Mdx/MLC Cre/IKK2fl/fl Increased muscle progenitor cells during regeneration [83]
Mdx/Lys Cre/IKK2fl/fl Reduces inflammation in dystrophic muscle [83]
Mdx/p50−/− No influence in mdx pathology [83]
Mdx/p65+/− mice Rescues mdx pathology [83]
Bcl3−/− mice Inhibits muscle atrophy (both fast and slow fibers affected) [45]
p50−/− mice Inhibits muscle atrophy (only fast fibers affected) [45]
c-Rel−/− mice No influence during atrophy [44]
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cle injury. Based on this evidence, it was suggested that the
role of NF-κB activity, which is present in dystrophic
patients, is very likely to arise from both immune cells and
muscle fibers.
From the muscle-specific effects of different genetic
mouse models, it is clear that tissue-specific manipulations
of NF-κB signaling provide valuable information in dissect-
ing more accurately the NF-κB pathway in muscle physiol-
ogy and disease. The question that arises is whether our
current knowledge of NF-κB signaling in skeletal muscle is
sufficient to initiate pharmacological interventions.
Pharmacological manipulation of the NF-κB pathway
in skeletal muscle disease models
The NF-κB signaling pathway has provided a target for
pharmacological invention and over 750 inhibitors of this
pathway have been identified, including a variety of natural
and synthetic molecules [89]. Many therapeutic trials have
been undertaken using NF-κB-dependent modulators
(Table 2) with the purpose of ameliorating the pathology
of muscular dystrophies as well as other muscle diseases.
The approaches that have been attempted in animal
models include components that interfere with TNF activity,
such as Remicade (an antibody) or Enbrel (a soluble TNF
receptor) [90, 91], aiming to block the acute inflammatory
cell response during whole muscle graft experiments in
mice. Enbrel appeared to be more effective than Remicade
in blocking TNF-α function and reducing the inflammation
response, but both drugs were able to reduce the breakdown
of dystrophic muscles in treated mdx mice [91]. Converse-
ly, treatments that induce TNF activity, such as direct TNF
gene transfer by electroporation into mouse muscle,
inhibited skeletal muscle regeneration in a model of freeze
injury [92]. Thus, TNF treatment might be a controversial
target for immunotherapy for DMD, since the effects are
not consistent.
In 1999, Thallor et al. suggested that systemic treatment
with curcumin, which acts as an NF-κB inhibitor, led to
faster restoration of normal muscle architecture as well as
increased expression of biochemical markers associated
with muscle regeneration [93], when administered after
local muscle injury. Recently, another group investigated
the effects of NF-κB blocking by pyrrolidine dithiocarba-
mate (PDTC), a synthetic antioxidant that acts as another
NF-κB inhibitor in mdx mice. This treatment increased
forelimb strength, decreased fatigue percentage, reduced
muscle necrosis, and enhanced muscle regeneration in mdx
mice [93]. However, it is well known that curcumin induces
several other transcription factors, such as activating protein
1 (AP-1) [94] or nuclear respiratory factor 2 (Nrf2) [95] and
PDTC also induces Nrf2 [96]. Therefore, although curcu-
min and PDTC might produce beneficial effects in skeletal
muscles, it is likely that these effects might be the result of
additional pathways than only NF-κB activity.
Even more recent evidence showed that pharmacological
inhibition at the level of the IKK subunits by using the cell-
permeable NEMO-binding domain (NBD) peptide, during
the pre-necrotic phase in mdx mice, was sufficient to
decrease macrophage infiltration and sarcoplasmic mem-
brane lysis [83]. Moreover, if treatment was pursued during
the post-necrotic phase, in addition to the high reduction in
immune cell infiltration, the number of newly forming
fibers was increased and the electrophysiological properties
of the affected muscles were improved [83]. Therefore,
pharmacological blockade of NF-κB produces beneficial
effects on functional, biochemical, and morphological
parameters of dystrophic muscles and targeting the IKK/
NF-κB pathway could improve the secondary pathology of
DMD.
In the context of muscle atrophy, it was shown that
treatment with high dosages of sodium salicylate, a
component that has been shown to inhibit NF-κB [97],
the atrophy phenotype of the MIKK mice was diminished
[4]. However, sodium salicylate has a range of other targets
besides NF-κB [4, 98], and the high doses that are required
for sufficient reversal of the atrophy phenotype might give
other side effects.
Finally, two other pharmacological components, named
pentoxifylline and thalidomide, which work as TNF-a
blockers, have been evaluated in clinical trials of cachexia
[99, 100]. Thalidomide has shown promising results in
patients with cancer cachexia [100], while pentoxifylline
was evaluated in cancer cachexia patients without demon-
strating any benefit in a small group of patients [99]. In
addition, pentoxifylline is used in an on-going (phase II)
clinical trial against the pathology of DMD [104] (Table 3).
However, pentoxifylline acts also as a phosphodiesterase 4
inhibitor, increasing cAMP and stimulating PKA activity
[99], therefore the outcome of the pentoxifylline treatment
cannot be attributed exclusively to TNF-α inhibition.
The different pharmacological approaches that interfere
with the NF-κB signaling pathway (summarized in
Table 3) constitute attractive therapies for the dystrophic
phenotype in animal models; however, these applications
cannot yet be directly applied to human clinical trials.
Various precautions must be taken before these agents are
used to manipulate NF-κB signaling in different muscle
conditions since (a) there is not enough proof about the
specificity of the existing molecules, (b) long pharmaco-
logical inhibition of NF-κB signaling raises serious con-
cerns about the effects on the patient’s immune system, and
(c) different muscle conditions might require different
manipulations of NF-κB signaling in a more cell-type-
specific way.
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Conclusions
It is now becoming clear that in addition to its recognized
role as a key regulator of immune and inflammatory
responses, NF-κB has recently emerged as a decisive factor
in the muscle cell’s response to aging and disease.
Considering the past and current literature on the role of
NF-κB in skeletal muscle physiology and disease, a
pleitropic nature of this transcription factor becomes
evident, as NF-κB activity seems to directly regulate
MyoD, cyclin D1, and probably other molecules such as
MuRF1 upon atrophy conditions. Although this makes NF-
κB the subject of inquiry for many laboratories with diverse
interests and we continue to gain insights from parallel
efforts, it is fair to say that many more questions remain to
be answered. For example, which are the exact NF-κB
components specifically in muscle cells? Are there only
p65, p50, and Bcl3 and how they act differently under
different pathological conditions? Which are the genes that
NF-κB regulates in skeletal muscles? How are they
regulated in the transcriptional, post-transcriptional, trans-
lational, or even a post-translational level? Most of the
existing literature is only referring to the canonical NF-κB
pathway. Studies remain to be designed that investigate the
possibility of alternative pathways or IKK-independent
functions in skeletal muscles, which might explain why
the NF-κB pathway plays the villain in some muscle
diseases, such as DMD, while it is beneficial in others such
as LGMD2A.
The growing appreciation of the role of NF-κB in human
diseases raises additional questions. For example, how do
the different cell types in the muscle tissue coordinate their
NF-κB functions? Muscle regeneration is considered
successful when inflammatory cell infiltration after injury
is followed by muscle repair and growth. This process
involves activation, proliferation, and terminal differentia-
tion of satellite cells, followed by the ability of new axons
to reach the myofibers [79]. Therefore, it is essential to
understand in depth the relationship between the different
cells, as well as the contribution of NF-κB interactions with
other muscle-specific regulators. We have yet to be able to
distinguish the effects of NF-κB in muscle cells from other
cell types that are involved during the muscle healing
process. Given the fact that NF-κB subunits are expressed
in many different cell types under various muscle con-
ditions, it might be not surprising that the number of
functions in which an NF-κB may be involved will vary
depending upon the muscle state in which it is found. For
example under muscle regeneration conditions, TWEAK (a
TNF-like inducer) is secreted from the invading macro-
phages and can bind its receptor expressed in muscle cells,
promoting proliferation and activation of myoblasts, which
can in turn contribute to an inflammatory response by
producing additional chemoattractants [101]. No doubt that
a better understanding of the NF-κB signaling cascades that
are involved in specific muscle processes will be important
for the development of new generations of drugs with
higher efficiency, less side effects, and lower cost.
Table 3 NF-κB pharmacological models that interfere with muscular pathology
Pharmacological components Way of action Reported muscle effect Animal References
NBD peptide NEMO-specific inhibitor dystrophic Improving pathology Mice [83]
Salicylate IKKβ inhibitor but also has a range
of other targets
Severe reduction of muscle atrophy Mice [4]
Remicade Silencing TNF-α activity Reduced breakdown of dystrophic
muscle
Mice [90, 91]
Enbrel Silencing TNF-α activity Reduced inflammation Mice [91]
Curcumin NF-κB inhibitor also induces AP-1
and Nrf2
Stimulates muscle regeneration Mice [102]
Synthetic antioxidant also induces
Nrf2 pyrrolidine dithiocarbamate
(PDTC)
NF-κB inhibitor Ameliorates the dystrophic
phenotype
Mice [93]
mTNFα gene transfer Induce TNF activity Induces cachexia, inhibits muscle
regeneration
Mice [92]
Thalidomide Inhibitor of TNF-α synthesis Attenuation of loss weight and
lean body mass in patients with
pancreatic cancer
Humans [100]
Pentoxifylline TNF-α inhibitor, also a PDE4 inhibitor
(increasing cAMP and stimulating
PKA activity)
No benefits Humans [99]
On-going clinical trial in DMD,
phase II
Humans [104]
AP-1 Activating protein 1, Nrf2 nuclear respiratory factor 2, PDE4 phosphodiesterase 4
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